Display options
Cite
Tan C, Wang Y, Fan W. Exploring polymeric micelles for improved delivery of anticancer agents: recent developments in preclinical studies. Pharmaceutics. 2013;5(1):201-19doi: 10.3390/pharmaceutics5010201.
Tan, C., Wang, Y., & Fan, W. (2013). Exploring polymeric micelles for improved delivery of anticancer agents: recent developments in preclinical studies. Pharmaceutics, 5(1), 201-19. https://doi.org/10.3390/pharmaceutics5010201
Tan, Chalet, et al. "Exploring polymeric micelles for improved delivery of anticancer agents: recent developments in preclinical studies." Pharmaceutics vol. 5,1 (2013): 201-19. doi: https://doi.org/10.3390/pharmaceutics5010201
Tan C, Wang Y, Fan W. Exploring polymeric micelles for improved delivery of anticancer agents: recent developments in preclinical studies. Pharmaceutics. 2013 Mar 22;5(1):201-19. doi: 10.3390/pharmaceutics5010201. PMID: 24300405; PMCID: PMC3834940.
Copy Download .nbib Format: NLM
Share it on

Pharmaceutics. 2013 Mar 22;5(1):201-19. doi: 10.3390/pharmaceutics5010201.

Exploring polymeric micelles for improved delivery of anticancer agents: recent developments in preclinical studies.

Pharmaceutics

Chalet Tan, Yingzhe Wang, Wei Fan

Affiliations

  1. Cancer Nanomedicine Laboratory, Department of Pharmaceutical Sciences, Mercer University, Atlanta, GA 30341, USA. [email protected].

PMID: 24300405 PMCID: PMC3834940 DOI: 10.3390/pharmaceutics5010201

Abstract

As versatile drug delivery systems, polymeric micelles have demonstrated particular strength in solubilizing hydrophobic anticancer drugs while eliminating the use of toxic organic solvents and surfactants. However, the true promise of polymeric micelles as drug carriers for cancer therapy resides in their potential ability to preferentially elevate drug exposure in the tumor and achieve enhanced anticancer efficacy, which still remains to be fully exploited. Here, we review various micellar constructs that exhibit the enhanced permeation and retention effect in the tumor, the targeting ligands that potentiate the anticancer efficacy of micellar drugs, and the polyplex micelle systems suitable for the delivery of plasmid DNA and small interference RNA. Together, these preclinical studies in animal models help us further explore polymeric micelles as emerging drug carriers for targeted cancer therapy.

References

  1. Mol Pharm. 2012 Sep 4;9(9):2646-57 - PubMed
  2. ACS Nano. 2011 Feb 22;5(2):1483-94 - PubMed
  3. Biomaterials. 2009 Oct;30(30):6006-16 - PubMed
  4. ACS Nano. 2012 Jun 26;6(6):5174-89 - PubMed
  5. J Control Release. 2006 May 30;112(3):329-32 - PubMed
  6. Biomaterials. 2012 Jun;33(18):4741-51 - PubMed
  7. J R Soc Interface. 2009 Jun 6;6 Suppl 3:S325-39 - PubMed
  8. Biochim Biophys Acta. 2011 Dec;1816(2):232-46 - PubMed
  9. Biomaterials. 2010 Mar;31(8):2371-9 - PubMed
  10. Mol Pharm. 2009 Sep-Oct;6(5):1277-89 - PubMed
  11. Curr Drug Deliv. 2011 Jan;8(1):2-10 - PubMed
  12. J Control Release. 2011 Oct 30;155(2):272-81 - PubMed
  13. J Control Release. 2007 Nov 6;123(2):109-15 - PubMed
  14. Nanomedicine. 2012 Aug;8(6):925-34 - PubMed
  15. Small. 2012 Jul 9;8(13):2060-9 - PubMed
  16. Exp Biol Med (Maywood). 2009 Feb;234(2):123-31 - PubMed
  17. Biochim Biophys Acta. 2012 Mar;1820(3):291-317 - PubMed
  18. Bioconjug Chem. 2013 Jan 16;24(1):133-43 - PubMed
  19. Int J Pharm. 2009 May 21;373(1-2):100-6 - PubMed
  20. Bioconjug Chem. 2010 Feb 17;21(2):208-13 - PubMed
  21. J Control Release. 2012 May 10;159(3):429-34 - PubMed
  22. Mol Pharm. 2010 Apr 5;7(2):501-9 - PubMed
  23. Biomaterials. 2011 Sep;32(25):5934-44 - PubMed
  24. Adv Drug Deliv Rev. 2013 Jan;65(1):121-38 - PubMed
  25. Biomaterials. 2011 Sep;32(27):6633-45 - PubMed
  26. Acc Chem Res. 2012 Jul 17;45(7):1014-25 - PubMed
  27. Biomaterials. 2010 Mar;31(8):2293-301 - PubMed
  28. Biomaterials. 2009 Jul;30(21):3614-25 - PubMed
  29. Mol Pharm. 2012 May 7;9(5):1175-88 - PubMed
  30. Cancer Res. 2002 Feb 1;62(3):867-74 - PubMed
  31. J Natl Cancer Inst. 2007 Jul 4;99(13):1004-15 - PubMed
  32. Cancer Res. 2012 Apr 15;72(8):2100-10 - PubMed
  33. J Control Release. 2010 Jun 1;144(2):259-66 - PubMed
  34. J Control Release. 2010 Oct 1;147(1):144-50 - PubMed
  35. Mol Pharm. 2009 Sep-Oct;6(5):1353-62 - PubMed
  36. Biomaterials. 2013 Jan;34(2):552-61 - PubMed
  37. J Control Release. 2012 Jun 28;160(3):542-51 - PubMed
  38. J Control Release. 2012 May 10;159(3):312-23 - PubMed
  39. Biomaterials. 2012 Feb;33(5):1489-99 - PubMed
  40. J Control Release. 2010 Apr 2;143(1):136-42 - PubMed
  41. Int J Pharm. 2009 Jun 5;374(1-2):114-8 - PubMed
  42. Cancer Res. 2007 Nov 15;67(22):10958-65 - PubMed
  43. Int J Pharm. 2012 Sep 15;434(1-2):413-9 - PubMed
  44. Int J Pharm. 2012 Jan 17;422(1-2):374-80 - PubMed
  45. Biomaterials. 2010 Oct;31(30):7797-804 - PubMed
  46. Nat Rev Cancer. 2010 Jan;10(1):9-22 - PubMed
  47. Biomaterials. 2011 Apr;32(11):3124-33 - PubMed
  48. J Drug Target. 2011 Jun;19(5):382-90 - PubMed
  49. J Control Release. 2011 May 30;152(1):2-12 - PubMed
  50. Nat Med. 2002 Jul;8(7):751-5 - PubMed
  51. PLoS One. 2013;8(3):e58619 - PubMed
  52. J Control Release. 2008 Jul 14;129(2):107-16 - PubMed
  53. Cancer Res. 2010 May 15;70(10):3896-904 - PubMed
  54. Adv Drug Deliv Rev. 2013 Jan;65(1):71-9 - PubMed
  55. J Control Release. 2011 Jan 5;149(1):51-7 - PubMed
  56. Nat Rev Genet. 2011 May;12(5):329-40 - PubMed
  57. Biomaterials. 2011 Apr;32(11):2894-906 - PubMed
  58. J Control Release. 2011 May 30;152(1):84-9 - PubMed
  59. Mol Med. 2000 Mar;6(3):165-78 - PubMed

Publication Types

Grant support